Richard B. Kim, MD, FRCPC, Division Chair
Dr. Kim received his medical degree from University of Saskatchewan, Canada in 1987. After completing an internship and residency training at Royal University hospital in Saskatoon Canada in 1991, he went on to carry out postdoctoral fellowship training in Clinical Pharmacology at Vanderbilt University.
In 1994, upon completion of his fellowship training, he remained at Vanderbilt Clinical Pharmacology as a faculty member until 2006. He is currently Professor and Chair of the Division of Clinical Pharmacology in the Department of Medicine at the University of Western Ontario in London, Canada. His research interest is that of understanding the molecular basis of interindividual differences in drug disposition and the application of such finding to the emerging field of Personalized Medicine.
Research areas under active investigation in his laboratory include that of drug transporters, CYP enzymes, and the pathways involved in the regulated expression of such proteins. He is a member of ASCPT, ISSX, and AAPS. He is an editor for the Medical Letter Handbook of Adverse Drug Interactions, and an associate editor for Molecular Pharmacology. He is a fellow of AAPS, and member of the American Society for Clinical Investigation (ASCI).

Publications
2005  2006  2007  2008  2009
<<<        >

Bailey D.G., Dresser G.K., Leake B.F., and Kim R.B.: Naringin is a major and selective clinical inhibitor of Organic Anion Transporting Polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 81:495-502, 2007. [Pubmed]

Glaeser, H., Bailey D.G., Dresser G.K., Gregor J.C., Schwarz U.I., McGrath J.S., Jolicoeur E., Lee W., Leake B.F., Tirona R.G., and Kim R.B.: Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81:362-70, 2007. [Pubmed]

Ho R.H., Choi L., Lee W., Mayo G., Schwarz U.I., Tirona R.G., Bailey D.G., Stein C.M., and Kim R.B.: Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics. 17:647-656, 2007. [Pubmed]

Leslie E.M., Watkins P.B., Kim R.B., and Brower K.L.R: Differential inhibition of rat and human Na+-dependent taurocholate co-transporting polypeptide (NTCP/SLC10A1) by bosentan: A mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321:1170-1178, 2007. [Pubmed]

Marzolini C., Tirona R.G., Gervasini G., Poonkuzhali B., Assem M., Lee W., Leake B.F., Schuetz J.D., Schuetz E.G., and Kim R.B.: A common polymorphism in the bile acid receptor FXR is associated with decreased hepatic target gene expression. Mol Endocrinol, 21:1769-1780, 2007. [Pubmed]

Mohler P.J., Le Scouarnec S., Denjoy I., Lowe J.S., Guicheney P., Caron L., Driskell I.M., Schott J.J., Norris K., Leehardt A., Kim R.B., Escande D., and Roden D.M.: Defining the Cellular Phenotype of Ankyrin-B Syndrome Variants. Human ANK2 Variants Associated With Clinical Phenotypes Display a Spectrum of Activities in Cardiomyocytes. Circulation 115:432-441, 2007 [Pubmed]

Schwarz U.I., Hanso H., Oertel R., Miehlke S., Kuhlisch E., Glaeser H., Hitzel M., Dresser G.K.., Kim R.B., and Kirch W.: Induction of intestinal P-glycoprotein by St.Johnâ??s wort reduces the oral bioavailability of talinolol. Clin. Pharmacol. Ther. 81:669-678, 2007. [Pubmed]

Urquhart B.L., Tirona R.G., and Kim R.B.: Nuclear receptors and the regulation of drug metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. J Clin Pharmacol, 47:566-578, 2007  [Pubmed]